The Carolina CCNE is focused on improving cancer disease control and management by utilizing exciting new and cutting edge nanotechnologies, developed from our first CCNE efforts,. Our efforts will work to improve the quality and duration of life and disease outcome for cancer patients by enhancing treatment and early detection. We propose five projects in two major areas as follows: Nano-Particle Based Biological and Chemotherapy includes Project 1: PRINT Nanoparticles: """"""""Calibration Quality"""""""" Nano-tools for Studying Particle Biodistribution, Project 2: Ras pathway siRNA in Lung Cancer, and Project 3: Translational Nanosystems Chemotherapy in Lung Cancer. Carbon Nanotube Based Radiation Therapy and Early Detection include Project 4: Compact Micro Beam Radiation Therapy in Brain Cancer and Project 5: Digital Breast Tomosynthesis System. The proposed nanoparticle science is primarily focused on targeted delivery of biological (siRNA) and chemotherapy to cancer cells. A key basic science question we will address is the implications of nanoparticle size, shape and modulus in accessing various tissues in the body. This question can effectively be answered by the UNC-developed PRINT technology, which features exquisite control over particle properties and will result in the establishment of BioMaps for nanoparticle delivery. Two additional nanoparticle-based projects will deliver biological and chemotherapy in a targeted fashion to lung cancer, with four distinct nanoparticle types that are capable of carrying multiple payloads. We will establish the first direct comparison of efficacy and toxicity of these various approaches against the equivalent of clinical standard of care in sophisticated murine cancer models. With carbon nanotube-based field emission X-ray technology, a new compact microbeam radiation therapy source is proposed that will deliver high intensity and spatially distributed radiotherapy to high grade gliomas and other brain cancers. Lastly, a carbon nanotube-based clinic-ready breast tomosynthesis imaging device is proposed that would advance early detection and characterization of breast abnormalities, and help to distinguish cancer from benign disease. We believe that developing these technologies and preparing them for clinical trials will help in realizing the promise of nanotechnology in cancer care and positively impact the lives of cancer patients. Public Health Relevance: Nanotechnology can be part of an improved cancer management effort. The need for targeted delivery systems, capable of carrying multiple and varied payloads, coupled with early detection, is a prerequisite for efficient therapy and reduced toxicity leading to improved outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA151652-01
Application #
7963527
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Program Officer
Grodzinski, Piotr
Project Start
2010-09-01
Project End
2015-07-31
Budget Start
2010-09-01
Budget End
2011-07-31
Support Year
1
Fiscal Year
2010
Total Cost
$2,590,876
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Liu, Lina; Wang, Yuhua; Miao, Lei et al. (2018) Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol Ther 26:45-55
Starling, Brittney R; Kumar, Parag; Lucas, Andrew T et al. (2018) Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. Cancer Chemother Pharmacol :
Chai, Zheng; Zhang, Xintao; Rigsbee, Kelly Michelle et al. (2018) Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration. J Control Release 286:415-424
Wang, Yuhua; Zhang, Lu; Xu, Zhenghong et al. (2018) mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Mol Ther 26:420-434
Pei, Xiaolei; He, Ting; Hall, Nikita E et al. (2018) AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement. Virology 518:95-102
Zhang, Xintao; He, Ting; Chai, Zheng et al. (2018) Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176:71-83
Lucas, Andrew T; White, Taylor F; Deal, Allison M et al. (2017) Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models. Nanomedicine 13:471-482
Kim, Junghyun; Luo, Zhi-Xiang; Wu, Yue et al. (2017) In-Situ Formation of Holmium Oxide in Pores of Mesoporous Carbon Nanoparticles as Substrates for Neutron-Activatable Radiotherapeutics. Carbon N Y 117:92-99
Huo, Meirong; Zhao, Yan; Satterlee, Andrew Benson et al. (2017) Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release 245:81-94

Showing the most recent 10 out of 190 publications